SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-015041
Filing Date
2024-05-31
Accepted
2024-05-31 16:18:25
Documents
1
Period of Report
2024-05-29

Document Format Files

Seq Description Document Type Size
1 form4-05312024_040510.html 4  
1 form4-05312024_040510.xml 4 6765
  Complete submission text file 0001415889-24-015041.txt   8351
Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902
Business Address
Stalfort John A III (Reporting) CIK: 0001709418 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 241009894

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)